July 24, 2020—Diaceutics announced two partnerships, with Targos Molecular Pathology and HistoCyte Laboratories, on its DXRX platform. an end-to-end solution for the development and commercialization of precision medicine diagnostics.
As a network partner to DXRX, Targos will provide laboratories with its Targos Advance Expert training and quality assurance support along with comparison studies and ring studies. Targos aims to enable laboratories to benchmark their performance against other laboratories and ensure that patients receive the same quality of testing. HistoCyte will help laboratories standardize and evaluate the performance of their immunohistochemistry and fluorescence in situ hybridization assays by providing single slide control materials.
“Too many patients are still missing out on getting the right treatment at the right time due to inefficiencies in the testing ecosystem. These partnerships will enable the diagnostic testing standardization and training support needed at a global level to make precision medicine treatments accessible to every patient,” Karina Hjort, senior director of innovation at Diaceutics, said in a press release.
Targos and HistoCyte’s services will be made to a select number of laboratories within Diaceutics’ network of more than 2,500 labs. The pilot collaboration will focus on PD-L1 testing.